Although our studies focus on CRCs, in vivo glutamine dependency may be a general phenomenon for various tumor types, as recent studies demonstrate that a variety of tumor types including breast, pancreatic, kidney cancers as well as acute myeloid leukemia are sensitive to a glutaminase inhibitor, CB-839, in vivo21–24. The gene discussed is GLS; the disease is acute myeloid leukemia.